1What Are DMARDs? — The First-Line Medicines for RA
DMARD stands for Disease-Modifying Anti-Rheumatic Drug. This name distinguishes them from ordinary painkillers (which only relieve symptoms) and steroids (which suppress inflammation broadly but do not modify the underlying disease course). DMARDs actually slow or stop the immune-driven joint destruction that defines RA.
How DMARDs work:
DMARDs are broad immunomodulatory agents — they modify the immune system's function in various ways to reduce the autoimmune attack on the joints. They are not specific to the RA pathway; they affect the immune system more widely, which is why they have effects (and side effects) across multiple organ systems.
The main conventional DMARDs used in RA:
Methotrexate (MTX)
The cornerstone of RA treatment globally. Used in RA since the 1980s. Works by inhibiting folate metabolism in rapidly dividing cells — primarily the immune cells driving inflammation.
Hydroxychloroquine (HCQ)
Originally an antimalarial, now used widely in mild RA and lupus. Works by modifying immune cell signalling in lysosomes.
Sulfasalazine
Anti-inflammatory and immunomodulatory. Often used in combination with MTX and HCQ ("triple therapy").
Leflunomide
An alternative to MTX when MTX is not tolerated. Inhibits pyrimidine synthesis.
Triple therapy (MTX + HCQ + Sulfasalazine):
Before biologics, combination conventional DMARD therapy was the next step when MTX alone failed. Studies show triple therapy performs comparably to adding a biologic in a significant proportion of patients — and at a fraction of the cost. Many guidelines recommend trying triple therapy before moving to biologics.
2What Are Biologics? — Targeted Medicines and Why They Are Different
Biologics are a fundamentally different class of medicine from conventional DMARDs. Rather than broadly modifying the immune system, biologics are engineered proteins — typically monoclonal antibodies — that target a specific molecule in the inflammatory cascade.
This targeting is the key difference: instead of dampening the whole immune system, a biologic blocks one specific signal. This makes biologics more potent in some ways (they work faster and more completely on the targeted pathway) and differently risky (they create specific immunosuppression rather than broad immunosuppression).
The main biologics used in RA:
TNF inhibitors — the largest class, targeting tumour necrosis factor alpha (TNF-α), a central inflammatory cytokine in RA:
IL-6 inhibitors — targeting interleukin-6, another central RA cytokine:
B-cell depletion:
T-cell co-stimulation block:
JAK inhibitors (small molecule targeted therapies — technically not biologics but classified with them in guidelines):
How fast do biologics work?
Faster than conventional DMARDs. Many patients notice improvement in 2–4 weeks. Significant response is usually clear by 3 months. If a biologic has not shown effect by 3–6 months, it is unlikely to work and switching to another class is considered.
Biosimilars in India:
Biosimilars — versions of biologics made by different manufacturers once patents expire — have made biologics significantly more accessible. Adalimumab biosimilars are available in India at substantially lower cost than originator products. This should be discussed with your rheumatologist.
3When Are Biologics Actually Needed? — The Honest Answer
This is the question most patients want answered directly: do I actually need to go on a biologic?
The current guideline approach (EULAR, ACR):
Biologics are indicated in RA when:
So the sequence is: MTX first → if inadequate response, add HCQ and/or sulfasalazine (triple therapy) → if still inadequate, then biologic.
What does "inadequate response" mean?
The treat-to-target approach sets a specific goal: remission (DAS28 < 2.6) or at minimum low disease activity (DAS28 < 3.2). If this target has not been reached at 6 months of optimal conventional DMARD therapy, escalation is appropriate.
Poor prognostic factors that might accelerate escalation:
In these cases, some rheumatologists initiate a biologic earlier — not waiting 6 months of MTX failure — because of the risk of rapid structural damage.
When biologics are sometimes recommended too quickly:
The honest answer is that escalation to biologics sometimes happens when conventional therapy has not been optimised. Reasons include:
If you are being recommended a biologic, it is reasonable to ask: "Have we reached the maximum tolerated dose of methotrexate? Have we tried adding hydroxychloroquine and sulfasalazine?"
Specific situations where biologics may be the right choice sooner:
4The Real Risks of Biologics — What Patients in India Need to Know
Biologics are powerful medicines. Understanding the specific risks — not vague "immune suppression" — helps make an informed decision.
1. Infection risk — the most important concern in India
All biologics increase the risk of serious bacterial infections, particularly:
2. Cancer risk — complicated and context-dependent
Long-term use of biologics has raised questions about lymphoma risk. The honest answer: RA itself increases lymphoma risk (due to chronic immune activation), and it has been difficult to separate the RA risk from the biologic risk in studies. Current evidence suggests a modest increase in non-melanoma skin cancer with some biologics. Haematological malignancy risk from biologics specifically is uncertain. JAK inhibitors have higher signals for cardiovascular events and some cancers in studies of older patients — cardiology review before starting in patients over 50.
3. Injection site and infusion reactions
Subcutaneous biologics cause local redness and swelling at injection sites — common and manageable. IV biologics (infliximab, rituximab) can cause infusion reactions — managed by pre-medication and controlled infusion rate.
4. Autoimmune side effects
Paradoxically, anti-TNF biologics occasionally trigger new autoimmune conditions — drug-induced lupus, demyelination (multiple-sclerosis-like lesions), inflammatory bowel disease flares. These are uncommon but require vigilance.
5. Cost — a major practical issue in India
Even with biosimilars, biologic therapy costs Rs. 15,000–60,000 per month in India. This is the dominant practical barrier for most Indian patients. This is a legitimate reason to thoroughly exhaust conventional DMARD options before escalating.
6. Monitoring requirements
Regular blood tests (CBC, LFT, lipids with JAK inhibitors), TB re-screening annually, and clinical monitoring. Missing monitoring undermines the safety of biologic therapy.
5Homoeopathy as an Alternative — Before Escalating to Biologics
The treatment ladder in conventional RA management — MTX → triple therapy → biologic → newer targeted agents — is a powerful framework, but it has limitations: each step is more expensive, more immunosuppressive, and harder to come off.
Homoeopathic constitutional treatment represents a different trajectory: not a rung on the escalation ladder, but an alternative pathway that attempts to work at the root — the immune dysregulation itself.
Where homoeopathy belongs in this discussion:
For patients who have been diagnosed with RA and are considering whether to start DMARDs, or are on low-dose DMARDs and want to avoid escalation, or are on a biologic and want to reduce dependence — constitutional homoeopathic treatment is a serious option to consider.
This is not a claim that homoeopathy can replace biologics in severe, rapidly progressing RA with erosive damage and functional deterioration. That would be dishonest and dangerous. The honest position:
How constitutional treatment works in RA:
The prescription is based not on "RA medicine" but on the complete constitutional picture — what makes this particular person's immune system misfire in this particular way. Two RA patients presenting to a homoeopathic physician will typically receive different medicines because their constitutional state, thermal sensitivity, emotional pattern, joint characteristics, and associated symptoms are different.
Key medicines that commonly appear (individually prescribed, never as a fixed RA protocol):
Rhus Toxicodendron — morning stiffness better from continued motion; restless; worse cold-damp
Bryonia — every motion painful; wants absolute rest; worse from any movement
Calcarea Carbonica — chilly, sweaty, overweight RA patients; worse cold, damp; joints swollen but not hot
Natrum Muriaticum — RA after grief, loss, emotional suppression; wants to be alone; joints that crack
Causticum — established disease with progressive stiffness and deformity; joint contractures
Colchicum — small joints, especially MCP and PIP; exquisitely sensitive to touch; worse autumn
Actaea Spicata — specific affinity for small joints of hands and wrists; wrists red, hot, swollen
Medorrhinum — RA with strong hereditary background; worse damp; better at the seaside; family history of arthritis
What to realistically expect:
In early-to-moderate RA: first response (less stiffness, fewer flare days) in 6–12 weeks; significant improvement in 3–6 months; sustained stability in 12–18 months. In long-standing RA: slower, but improvement in quality of life, fatigue, and flare pattern is typically the first gain.
The conversation about escalating to biologics should not happen in isolation from constitutional treatment options — because the two paths have very different cost, risk, and long-term profiles.